1 most recent filing and news item mentioning IKT. Updated every 60 seconds.
OfferingJul 14, 2026Neutral
Inhibikase sold 25 million shares to RA Capital Management for $50 million gross proceeds. The funds are intended to support the IMPROVE-PAH Phase 3 study through topline data.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.